BNP Paribas Financial Markets Takes $532,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

BNP Paribas Financial Markets purchased a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 95,424 shares of the company's stock, valued at approximately $532,000. BNP Paribas Financial Markets owned 0.21% of 4D Molecular Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of FDMT. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics during the 4th quarter valued at about $48,000. PNC Financial Services Group Inc. raised its stake in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after acquiring an additional 3,630 shares during the period. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 5,291.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after purchasing an additional 9,737 shares in the last quarter. Virtus ETF Advisers LLC boosted its position in shares of 4D Molecular Therapeutics by 173.9% in the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after purchasing an additional 6,560 shares during the period. Finally, Fox Run Management L.L.C. purchased a new stake in shares of 4D Molecular Therapeutics in the fourth quarter worth $69,000. Institutional investors own 99.27% of the company's stock.

Wall Street Analyst Weigh In

FDMT has been the topic of several research analyst reports. Chardan Capital lowered their price objective on 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. The Goldman Sachs Group decreased their target price on 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Barclays cut their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of 4D Molecular Therapeutics in a research report on Saturday, May 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $29.56.

4D Molecular Therapeutics Stock Performance

Shares of FDMT traded up $0.24 during mid-day trading on Thursday, hitting $3.71. 401,097 shares of the stock were exchanged, compared to its average volume of 833,552. The company has a market cap of $171.87 million, a PE ratio of -1.30 and a beta of 2.87. 4D Molecular Therapeutics, Inc. has a 52-week low of $2.24 and a 52-week high of $28.93. The firm has a 50-day moving average of $3.23 and a two-hundred day moving average of $4.83.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). On average, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.